Corixa ( CRXA) and GlaxoSmithKline ( GSK) said the Food and Drug Administration has approved Bexxar, a treatment for patients with non-Hodgkin's lymphoma, a form of cancer that affects the blood, bone marrow and lymphatic tissues.

The two companies will co-market Bexxar in the U.S. Corixa expects to be ready to start filling orders for Bexxar from cancer treatment centers in about 30 days.

Bexxar is a dual-action therapy that pairs the tumor-targeting ability of a cancer-killing monoclonal antibody, Tositumomab, and the therapeutic potential of radiation, Iodine-131. Combined, the agents initiate an immune response against the cancer and deliver a dose of radiation directly to tumor cells.

Non-Hodgkin's lymphoma is the sixth-leading cause of cancer-related deaths in the U.S.

Shares of Corixa were gaining 71 cents, or 10%, to $7.91 on the Nasdaq. Glaxo was down 27 cents to $40.38 on the New York Stock Exchange.